K
Kader Yagiz
Researcher at Cedars-Sinai Medical Center
Publications - 36
Citations - 1557
Kader Yagiz is an academic researcher from Cedars-Sinai Medical Center. The author has contributed to research in topics: Immune system & Immunotherapy. The author has an hindex of 21, co-authored 36 publications receiving 1407 citations. Previous affiliations of Kader Yagiz include University of Michigan & Purdue University.
Papers
More filters
Journal ArticleDOI
HMGB1 Mediates Endogenous TLR2 Activation and Brain Tumor Regression
James F. Curtin,James F. Curtin,Naiyou Liu,Naiyou Liu,Marianela Candolfi,Marianela Candolfi,Weidong Xiong,Weidong Xiong,Hikmat Assi,Hikmat Assi,Kader Yagiz,Kader Yagiz,Matthew R. Edwards,Kathrin S. Michelsen,Kurt M. Kroeger,Kurt M. Kroeger,Chunyan Liu,Chunyan Liu,A.K.M. Ghulam Muhammad,A.K.M. Ghulam Muhammad,Mary C. Clark,Mary C. Clark,Moshe Arditi,Begonya Comin-Anduix,Antoni Ribas,Pedro R. Lowenstein,Maria G. Castro +26 more
TL;DR: Evidence is provided for the molecular and cellular mechanisms that support the rationale for the clinical implementation of antibrain cancer immunotherapies in combination with tumor killing approaches in order to elicit effective antitumor immune responses, and thus, will impact clinical neuro-oncology practice.
Journal ArticleDOI
Gene Therapy and Targeted Toxins for Glioma
Maria G. Castro,Marianela Candolfi,Kurt M. Kroeger,Gwendalyn D. King,James F. Curtin,Kader Yagiz,Yohei Mineharu,Hikmat Assi,Mia Wibowo,A.K.M. Ghulam Muhammad,David Foulad,Mariana Puntel,Pedro R. Lowenstein +12 more
TL;DR: This review will examine the available preclinical models for glioma including xenographs, syngeneic and genetic models to determine which strategies will provide rapid tumor regression and long-term protection from recurrence.
Journal ArticleDOI
Release of HMGB1 in response to proapoptotic glioma killing strategies: efficacy and neurotoxicity.
Marianela Candolfi,Kader Yagiz,David Foulad,Gabrielle E. Alzadeh,Matthew Tesarfreund,A.K.M. Ghulam Muhammad,Mariana Puntel,Kurt M. Kroeger,Chunyan Liu,Sharon Lee,James F. Curtin,Gwendalyn D. King,Jonathan Lerner,Katsuaki Sato,Yohei Mineharu,Weidong Xiong,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: The results indicate that Ad-TK+GCV+Ad-Flt3L exhibit the highest efficacy and safety profile among the several proapoptotic approaches tested.
Journal ArticleDOI
Gene therapy-mediated delivery of targeted cytotoxins for glioma therapeutics
Marianela Candolfi,Weidong Xiong,Kader Yagiz,Chunyan Liu,Akm Ghulam Muhammad,Mariana Puntel,David Foulad,Ali Zadmehr,Gabrielle E. Ahlzadeh,Kurt M. Kroeger,Matthew Tesarfreund,Sharon Lee,Waldemar Debinski,Dhruv Sareen,Clive N. Svendsen,Ronald Rodriguez,Pedro R. Lowenstein,Maria G. Castro +17 more
TL;DR: A regulatable adenoviral vector encoding a mutated human IL-13 fused to Pseudomonas exotoxin that specifically binds to IL13Rα2 to provide sustained expression, effective anti-GBM cytotoxicity, and minimal neurotoxicity is developed, representing a significant advance in the development of targeted therapeutics for GBM.
Journal ArticleDOI
B Cells Are Critical to T-cell—Mediated Antitumor Immunity Induced by a Combined Immune-Stimulatory/Conditionally Cytotoxic Therapy for Glioblastoma
Marianela Candolfi,James F. Curtin,Kader Yagiz,Hikmat Assi,Mia Wibowo,Gabrielle E. Alzadeh,David Foulad,Akm Ghulam Muhammad,Sofia Salehi,Sofia Salehi,Naomi Keech,Naomi Keech,Mariana Puntel,Chunyan Liu,Nicholas R. Sanderson,Kurt M. Kroeger,Robert Dunn,Gislaine Martins,Pedro R. Lowenstein,Maria G. Castro +19 more
TL;DR: This article showed that modifying the tumor microenvironment through intratumoral administration of adenoviral vectors (Ad) encoding the conditional cytotoxic molecule, i.e., HSV1-TK and the immune-stimulatory cytokine (Flt3L) leads to T-cell-dependent tumor regression in rodent models of glioblastoma.